Scholar Rock Holding Corp

SRRK

Scholar Rock Holding Corp

SRRK

Insider Sentiment (TTM):

Last Purchase:2025-10-07Last Sale:2026-04-16Shares Purchased (TTM):142,624Shares Sold (TTM):415,960

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:126,120,930Shares Outstanding:127,277,144Institutional Ownership Pct.:99.09%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	437	431	324	287	153	138	178	76	93	92	102	68
Marketable Securities Current	55	49	44	83	142	226	259	63	97	146	178	151
Prepaid Expense And Other Assets Current	15	35	18	21	24	21	14	14	9	9	8	10
Assets Current	507	515	385	391	319	385	451	153	199	247	288	228
Property Plant And Equipment Net	1	1	2	2	2	3	3	3	4	4	5	5
Operating Lease Right Of Use Asset	9	10	10	12	13	14	16	17	18	10	11	13
Restricted Cash Noncurrent	4	4	4	4	2	2	2	2	2	2	2	3
Other Assets Noncurrent	3	5	3	3	3	3	3	4	4	4	4	1
Assets	524	535	404	412	340	408	475	179	227	267	311	251
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	11	9	10	7	1	4	10	4	3	3	3	2
Accrued Liabilities Current	55	44	40	50	44	28	31	29	22	21	20	17
Operating Lease Liability Current	6	6	6	5	5	5	6	6	6	8	7	7
Short Term Borrowings	-	-	-	-	-	-	-	-	2	6	1	-
Other Liabilities Current	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities Current	72	60	55	62	50	38	47	39	33	38	33	27
Operating Lease Liability Noncurrent	1	3	4	5	7	8	9	10	12	2	4	6
Long Term Debt Noncurrent	196	197	100	100	50	50	50	50	48	45	49	50
Liabilities	270	259	159	167	107	95	106	100	93	85	86	83
Stockholders Equity
Preferred Stock Value	0	-	-	-	-	-	-	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,769	1,681	1,546	1,454	1,341	1,310	1,291	935	925	916	901	798
Accumulated Other Comprehensive Income Loss Net Of…	1	1	0	0	0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-1,516	-1,406	-1,301	-1,210	-1,107	-997	-923	-856	-792	-733	-676	-630
Stockholders Equity	254	276	245	245	233	312	369	79	134	183	225	168
Liabilities And Stockholders Equity	524	535	404	412	340	408	475	179	227	267	311	251
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	-	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	150	150	300	150
Common Stock Shares Issued	122	119	108	99	96	95	94	80	80	80	76	56
Shares Outstanding	122	119	108	99	96	95	94	80	80	80	76	56

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	6.14%	17.89%	2.63%	-	-	-	-	-	-	-	-	-
2025	12.08%	17.85%	19.06%	-5.68%	11.95%	-14.26%	20.34%	14.41%	18.52%	-3.86%	4.90%	8.62%
2024	-36.08%	-43.29%	-36.83%	13.83%	6.85%	266.10%	63.50%	69.43%	51.46%	-8.09%	-14.49%	-15.04%
2023	-	-	-	3.28%	16.58%	69.79%	8.91%	52.23%	18.30%	-11.22%	-11.88%	-37.23%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.02	8.64	6.95	6.30	6.33	10.25	9.61	3.88	6.04	6.58	8.80	8.55
Quick Ratio	6.81	8.05	6.63	5.96	5.85	9.70	9.32	3.53	5.77	6.36	8.55	8.18
Working Capital	434.94M	455.64M	329.73M	328.74M	268.69M	347.67M	404.23M	113.56M	166.15M	209.43M	255.45M	201.74M
Leverage & Debt
Debt to Equity	1.06	0.94	0.65	0.68	0.46	0.30	0.29	1.26	0.70	0.46	0.38	0.50
Interest Coverage TTM	-38.02	-55.52	-55.80	-46.81	-39.69	-31.28	-36.87	-66.70	-122.23	-	-	-
Debt Ratio	0.52	0.48	0.39	0.40	0.31	0.23	0.22	0.56	0.41	0.32	0.28	0.33
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-3.13	-3.21	-3.29	-3.11	-2.80	-2.36	-2.47	-2.33	-2.11	-1.91	-1.99	-1.97
Free Cash Flow Per Share TTM	-2.25	-2.39	-2.62	-1.72	-1.59	-2.06	-2.01	-1.95	-1.74	-1.59	-1.74	-1.70
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-	-	-100.00%	-100.00%
Net Income Growth (1Y)	29.43%	54.72%	53.45%	56.41%	54.87%	44.14%	48.56%	42.19%	27.52%	10.45%	23.26%	21.16%
EPS Growth (1Y)	11.68%	35.96%	33.57%	33.47%	33.03%	23.59%	24.02%	18.10%	5.53%	-8.31%	-11.84%	19.25%
Valuation Metrics
P/E TTM	-17.58	-15.31	-13.37	-11.98	-12.65	-13.61	-17.52	-3.44	-3.96	-9.29	-9.45	-3.60
P/B TTM	28.31	22.67	20.58	17.29	17.11	11.51	11.71	9.82	6.04	9.32	6.96	3.41
Market Cap	7.18B	6.26B	5.05B	4.24B	3.99B	3.60B	4.32B	777.38M	806.45M	1.70B	1.57B	572.31M
Enterprise Value	6.94B	6.02B	4.82B	4.04B	3.89B	3.51B	4.18B	748.68M	760.75M	1.66B	1.51B	552.05M
Calculated Values
Free Cash Flow TTM	-293.92M	-303.97M	-300.75M	-195.81M	-179.29M	-230.19M	-201.05M	-188.86M	-168.65M	-152.02M	-145.30M	-136.97M
Net Debt	-244.70M	-237.74M	-227.63M	-190.97M	-105.58M	-90.59M	-130.14M	-28.70M	-45.71M	-44.29M	-54.24M	-20.25M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-16Sale

Owner: Vaishnaw, Akshay

Title: President of R&D

Shares: 12,246

Price/Share: $49.57

Value: $607,034.22

Shares Owned: 630,542

Relationship: Director,Officer

Ownership: Direct

2026-04-16Sale

Owner: Sinha, Vikas

Title: Chief Financial Officer

Shares: 10,410

Price/Share: $49.57

Value: $516,023.70

Shares Owned: 619,856

Relationship: Officer

Ownership: Direct

2026-04-16Sale

Owner: Hallal, David

Title: Chief Executive Officer

Shares: 30,615

Price/Share: $49.57

Value: $1,517,585.55

Shares Owned: 1,639,034

Relationship: Director,Officer

Ownership: Direct

2026-04-16Sale

Owner: Woods, Keith

Title: Chief Operating Officer

Shares: 10,220

Price/Share: $49.57

Value: $506,605.40

Shares Owned: 620,055

Relationship: Officer

Ownership: Direct

2026-02-23Sale

Owner: Qatanani, Mo

Title: CHIEF SCIENTIFIC OFFICER

Shares: 8,484

Price/Share: $47.76

Value: $405,195.84

Shares Owned: 98,445

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-16	Vaishnaw, Akshay	Director,Officer	President of R&D	Direct	Sale	12,246	49.57	$607,034.22	630,542	4
2026-04-16	Sinha, Vikas	Officer	Chief Financial Officer	Direct	Sale	10,410	49.57	$516,023.70	619,856	4
2026-04-16	Hallal, David	Director,Officer	Chief Executive Officer	Direct	Sale	30,615	49.57	$1,517,585.55	1,639,034	4
2026-04-16	Woods, Keith	Officer	Chief Operating Officer	Direct	Sale	10,220	49.57	$506,605.40	620,055	4
2026-02-23	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	8,484	47.76	$405,195.84	98,445	4
2026-02-17	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	9,035	46.53	$420,398.55	169,087	4
2026-02-17	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	9,580	46.53	$445,757.40	241,545	4
2026-02-17	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	7,989	46.53	$371,728.17	106,929	4
2026-02-17	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,157	46.53	$193,425.21	126,012	4
2026-01-22	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	14,898	46.36	$690,671.28	85,660	4
2026-01-16	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	8,016	44.48	$356,551.68	214,553	4
2026-01-16	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,798	44.48	$257,895.04	95,687	4
2026-01-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	6,600	44.48	$293,568.00	148,864	4
2026-01-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	8,406	44.48	$373,898.88	100,558	4
2026-01-14	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	13,112	45.20	$592,662.40	108,964	4
2026-01-13	Woods, Keith	Officer	Chief Operating Officer	Direct	Sale	16,746	42.70	$715,054.20	583,254	4
2026-01-13	Sinha, Vikas	Officer	Chief Financial Officer	Direct	Sale	16,755	42.70	$715,438.50	583,245	4
2026-01-13	Vaishnaw, Akshay	Director,Officer	President of R&D	Direct	Sale	20,438	42.70	$872,702.60	595,767	4
2026-01-13	Hallal, David	Director,Officer	Chief Executive Officer	Direct	Sale	57,450	42.70	$2,453,115.00	1,541,645	4
2025-12-16	Peng, Katie	Director	-	Direct	Sale	1,006	44.26	$44,525.56	32,908	4
2025-12-04	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	136,462	45.21	$6,169,447.02	108,964	4
2025-10-07	Akkaraju, Srinivas	Director	-	Indirect	Purchase	29,599	40.15	$1,188,399.85	530,038	4
2025-10-06	Akkaraju, Srinivas	Director	-	Indirect	Purchase	113,025	38.70	$4,374,067.50	500,439	4
2025-09-22	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	3,353	30.67	$102,836.51	108,964	4
2025-09-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	3,178	33.52	$106,526.56	112,317	4
2025-09-16	Peng, Katie	Director	-	Direct	Sale	1,006	32.84	$33,037.04	33,914	4
2025-08-18	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	2,178	31.17	$67,888.26	155,464	4
2025-07-16	Flier, Jeffrey S.	Director	-	Indirect	Sale	11,136	40.02	$445,662.72	0	4
2025-07-08	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	24,066	34.44	$828,833.04	115,495	4
2025-06-23	Flier, Jeffrey S.	Director	-	Direct	Sale	20,316	32.45	$659,254.20	24,070	4
2025-06-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	3,668	32.00	$117,376.00	139,561	4
2025-06-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	6,186	32.00	$197,952.00	157,642	4
2025-06-16	Peng, Katie	Director	-	Direct	Sale	3,031	32.25	$97,749.75	34,920	4
2025-06-16	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	7,442	32.00	$238,144.00	222,569	4
2025-05-29	Burow, Kristina	Director	-	Direct	Sale	5,400	29.53	$159,462.00	21,071	4
2025-05-29	Vaishnaw, Akshay	Director,Officer	President of R&D	Direct	Sale	6,750	29.82	$201,285.00	616,205	4
2025-05-29	Reed, Joshua	Director	-	Direct	Sale	5,400	29.86	$161,244.00	15,732	4
2025-05-29	Gilman, Michael	Director	-	Direct	Sale	3,375	29.52	$99,630.00	55,216	4
2025-05-29	Brudnick, Richard	Director	-	Direct	Sale	6,075	29.82	$181,156.50	15,057	4
2025-05-29	Flier, Jeffrey S.	Director	-	Direct	Sale	6,075	29.54	$179,455.50	24,070	4
2025-04-25	Sacco, Tracey	Officer	Chief Commercial Officer	Direct	Sale	5,000	33.15	$165,750.00	71,750	4
2025-03-24	Sacco, Tracey	Officer	Chief Commercial Officer	Direct	Sale	6,500	33.30	$216,450.00	71,750	4
2025-03-24	Moore, Erin	Officer	Interim PFO and PAO	Direct	Sale	13,564	33.12	$449,239.68	82,609	4
2025-03-17	Peng, Katie	Director	-	Direct	Sale	1,006	34.42	$34,626.52	30,319	4
2025-03-10	Myles, Edward H	Officer	COO & CFO	Direct	Sale	142,292	35.34	$5,028,599.28	111,345	4
2025-02-19	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	68,510	37.50	$2,569,125.00	111,084	4
2025-02-18	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	5,742	36.83	$211,477.86	189,295	4
2025-02-18	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	5,296	36.83	$195,051.68	140,258	4
2025-02-18	Backstrom, Jay T.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	18,372	36.83	$676,640.76	311,991	4
2025-02-18	Myles, Edward H	Officer	COO & CFO	Direct	Sale	7,809	36.83	$287,605.47	140,740	4
2025-01-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	7,347	44.20	$324,737.40	135,421	4
2025-01-16	Backstrom, Jay T.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	22,308	44.20	$986,013.60	330,363	4
2025-01-16	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	9,039	44.20	$399,523.80	195,037	4
2025-01-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	6,434	44.20	$284,382.80	145,554	4
2025-01-16	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,655	44.20	$249,951.00	67,200	4
2025-01-16	Sacco, Tracey	Officer	Chief Commercial Officer	Direct	Sale	3,890	44.20	$171,938.00	45,395	4
2025-01-16	Myles, Edward H	Officer	COO & CFO	Direct	Sale	12,539	44.20	$554,223.80	148,549	4
2024-12-10	Invus, Global Management,…	TenPercentOwner	-	Direct	Sale	1,600,000	41.65	$66,640,000.00	9,250,005	4
2024-11-25	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,375	39.48	$251,685.00	72,855	4
2024-11-25	Invus, Public Equities Ad…	TenPercentOwner	-	Direct	Sale	409,433	39.34	$16,107,094.22	10,850,005	4
2024-11-11	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,105	30.00	$63,150.00	72,855	4
2024-10-08	Myles, Edward H	Officer	COO & CFO	Direct	Sale	37,187	34.90	$1,297,826.30	161,088	4
2024-10-07	Akkaraju, Srinivas	Director	-	Indirect	Sale	1,175,713	30.00	$35,271,390.00	5,612,896	4
2024-10-07	Marantz, Jing L.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	109,375	27.29	$2,984,843.75	72,855	4
2024-10-07	Sacco, Tracey	Officer	CHIEF COMMERCIAL OFFICER	Direct	Sale	30,000	25.90	$777,000.00	49,285	4
2024-10-07	Myles, Edward H	Officer	COO & CFO	Direct	Sale	206,240	27.19	$5,607,665.60	161,088	4
2024-09-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	1,936	8.58	$16,610.88	142,768	4
2024-08-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	1,451	9.33	$13,537.83	151,988	4
2024-06-17	Myles, Edward H	Officer	COO & CFO	Direct	Sale	9,458	8.98	$84,932.84	201,518	4
2024-06-17	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,315	8.99	$20,811.85	144,704	4
2024-06-17	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	4,695	8.98	$42,161.10	204,076	4
2024-06-17	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	4,305	8.98	$38,658.90	153,439	4
2024-02-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	3,751	15.74	$59,040.74	157,744	4
2024-02-16	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	3,489	15.74	$54,916.86	208,771	4
2024-02-16	Myles, Edward H	Officer	COO & CFO	Direct	Sale	4,744	15.74	$74,670.56	210,976	4
2024-02-16	Qatanani, Mo	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,512	15.74	$39,538.88	147,019	4
2024-02-16	Backstrom, Jay T.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	11,614	15.74	$182,804.36	352,671	4
2024-01-16	Qatanani, Mo	Officer	SVP AND HEAD OF RESEARCH	Direct	Sale	2,002	15.93	$31,891.86	78,816	4
2024-01-16	Ho, Junlin	Officer	GENERAL COUNSEL	Direct	Sale	4,186	15.93	$66,682.98	154,405	4
2024-01-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	2,849	15.93	$45,384.57	114,350	4
2024-01-16	Myles, Edward H	Officer	COO & CFO	Direct	Sale	6,634	15.93	$105,679.62	162,150	4
2023-12-29	Myles, Edward H	Officer	COO & CFO	Direct	Sale	12,459	19.16	$238,714.44	168,784	4
2023-12-14	Qatanani, Mo	Officer	SVP AND HEAD OF RESEARCH	Direct	Sale	24,662	18.18	$448,355.16	80,818	4
2023-12-07	Myles, Edward H	Officer	COO & CFO	Direct	Sale	24,914	17.53	$436,742.42	168,784	4
2023-11-02	Myles, Edward H	Officer	COO & CFO	Direct	Sale	35,007	12.51	$437,937.57	168,784	4
2023-10-16	Samsara, Biocapital Gp, L…	TenPercentOwner	-	Indirect	Purchase	2,189,781	6.85	$14,999,999.85	6,788,609	4
2023-10-16	Akkaraju, Srinivas	Director,TenPercentOwner	-	Indirect	Purchase	2,189,781	6.85	$14,999,999.85	6,788,609	4
2023-10-12	Wittouck, Amaury, Artal G…	TenPercentOwner	-	Direct	Purchase	2,199,931	7.70	$16,939,468.70	11,259,438	4
2023-09-18	Qatanani, Mo	Officer	SVP AND HEAD OF RESEARCH	Direct	Sale	1,945	6.34	$12,331.30	97,043	4
2023-08-16	Parlavecchio, Caryn	Officer	CHRO	Direct	Sale	1,353	6.83	$9,240.99	117,199	4
2023-04-28	Artal, International Mana…	TenPercentOwner	-	Direct	Purchase	31,557	6.43	$202,911.51	9,059,507	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

99.09%

Inst. Shares: 126,120,930

Shares Outstanding: 127,277,144

2025-12-31

101.02%

Inst. Shares: 115,871,826

Shares Outstanding: 114,701,154

2025-09-30

95.69%

Inst. Shares: 108,828,604

Shares Outstanding: 113,729,850

2025-06-30

88.81%

Inst. Shares: 100,093,376

Shares Outstanding: 112,703,014

2025-03-31

83.68%

Inst. Shares: 93,581,601

Shares Outstanding: 111,838,272

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	126,120,930	127,277,144	99.09%
2025-12-31	115,871,826	114,701,154	101.02%
2025-09-30	108,828,604	113,729,850	95.69%
2025-06-30	100,093,376	112,703,014	88.81%
2025-03-31	93,581,601	111,838,272	83.68%
2024-12-31	93,306,969	99,838,102	93.46%
2024-09-30	77,130,658	97,050,637	79.47%
2024-06-30	76,410,334	96,813,116	78.93%
2024-03-31	75,788,082	95,892,601	79.03%
2023-12-31	60,647,487	83,347,086	72.76%
2023-09-30	37,410,900	80,606,438	46.41%
2023-06-30	32,160,034	80,117,983	40.14%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Scholar Rock Holding Corp (SRRK) — SEC Financial Statements & Analysis

Scholar Rock Holding Corp (SRRK) is a biological products, (no diagnostic substances) company, incorporated in DE. Scholar Rock Holding Corp trades on Nasdaq as: SRRK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Scholar Rock Holding Corp reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 1.06x, a Price-to-Book (P/B) ratio of 28.31x (TTM), at a market cap of $7.18B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 1.06x
P/B TTM: 28.31x
Market Cap: $7.18B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Scholar Rock Holding Corp in?

Scholar Rock Holding Corp (SRRK) operates in the Biological Products, (No Diagnostic Substances) industry.

What is SRRK's market cap?

Scholar Rock Holding Corp (SRRK) has a market capitalization of $7.18B as of 2026-06-30.

What exchange does SRRK trade on?

Scholar Rock Holding Corp (SRRK) trades on the Nasdaq.

Where is Scholar Rock Holding Corp incorporated?

Scholar Rock Holding Corp is incorporated in DE.